Pharmacotherapy of Personality Disorders
Psychotherapy, not pharmacotherapy, is the primary treatment for personality disorders, with medications reserved only for targeting specific symptom domains or treating comorbid psychiatric conditions. No medications are FDA-approved for personality disorders themselves, and the evidence does not support treating the core personality pathology with drugs 1, 2, 3.
Core Principle: Symptom-Targeted Approach
The fundamental approach is to identify and treat specific symptom clusters rather than the personality disorder diagnosis itself. The strongest evidence exists for borderline personality disorder (BPD), with limited data for other personality disorders 2, 3.
Target Symptom Domains and Corresponding Medications
For Impulsivity and Aggression (strongest evidence):
- Second-generation antipsychotics are first-line for impulsive-aggressive symptoms 2, 3
- Aripiprazole, olanzapine, or ziprasidone
- Caution: Olanzapine causes significant weight gain and sedation; monitor closely 3
- Mood stabilizers as alternatives 2, 3, 4
For Affective Dysregulation:
- SSRIs (fluoxetine, fluvoxamine) for emotional instability 3, 4
- Consider mood stabilizers if genetic link to bipolar disorder is suspected 5
- Avoid tricyclic antidepressants - SSRIs are preferred 4
For Psychotic-like Symptoms (ideas of reference, paranoia, dissociation):
- Second-generation antipsychotics at modest doses 2, 4
- Particularly relevant in schizotypal personality disorder 2, 6
For Anxiety Symptoms:
Critical Prescribing Rules
What NOT to do:
- Never use benzodiazepines routinely - high risk of dependence and disinhibition in this population 3, 4
- Avoid polypharmacy - use single agents targeting specific symptoms 1, 4
- Do not prescribe medications with overdose risk in patients with self-harm behaviors 1
- Do not use antidepressants for mild symptoms without clear depressive episode 7
Comorbidity-Driven Treatment
Since comorbid psychiatric disorders are the primary indication for medication 1:
Major Depressive Episode (moderate-severe):
- SSRIs (fluoxetine) or TCAs only if clear depressive episode present 7
- Continue 9-12 months after recovery 7
Bipolar Disorder Features:
- Lithium or valproate for maintenance 5
- Requires laboratory monitoring capability
- Consider if strong family history present 5
ADHD (common developmental pathway):
- Stimulants have specific role, particularly in antisocial personality disorder with childhood ADHD 8
Substance Use Disorder:
- Address substance abuse programs first 5
- Medications are adjunctive only
Duration and Monitoring
- Medications induce only partial improvement in symptom domains 2
- Long-term use has not been adequately studied 3
- Most trials were short-term; chronic use requires careful risk-benefit assessment 4
- Monitor for adverse effects, particularly metabolic changes with second-generation antipsychotics 3
Special Considerations
Borderline Personality Disorder has the most evidence, with suggestive support for second-generation antipsychotics, mood stabilizers, and omega-3 fatty acids 3. However, core BPD symptoms (chronic emptiness, identity disturbance, abandonment fears) do not respond to medication 3.
Antisocial Personality Disorder: Second-generation antipsychotics, lithium, anti-epileptic drugs, and stimulants (if ADHD present) target aggression and impulsivity 8.
Schizotypal Personality Disorder: Atypical antipsychotics for cognitive-perceptual symptoms 2, 6.
The Bottom Line
Prescribe medications only as adjuncts to personality disorder-specific psychotherapy 1. Target discrete symptoms (impulsivity, aggression, affective instability, psychotic-like symptoms) rather than the personality disorder itself. Use single agents at the lowest effective dose, avoid unsafe medications, and maintain realistic expectations about partial symptom improvement only.